Yuan Xiaoling, Hou Xianghe, Guo Weihong, Jiang Haiming, Zheng Junmeng, Paudyal Stuti, Lyu Yanhua
Respiratory Department Pathology Department Cardiothoracic Surgery, People's Hospital of Zhongshan City, Zhongshan City Medical Intern, Sun Yat-Sen University, China.
Medicine (Baltimore). 2017 Mar;96(13):e6507. doi: 10.1097/MD.0000000000006507.
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary arterial hypertension (PAH). Oral anticoagulation is confined to patients with idiopathic PAH (IPAH), but no oral anticoagulation has been recommended for PVOD, because occult pulmonary hemorrhage was a common finding in PVOD.
We report a case of PVOD, who was misdiagnosed as IPAH for 5 years with worsening dyspnea and two episodes of pulmonary embolism (PE).
He was confirmed as PVOD combined with PE by biopsy of the explanted lung specimen.
He took oral anticoagulation, warfarin, to treat his first-time PE in July 2010, and his disease was kept stable for about 4 years, until he discontinued the anticoagulation therapy by himself sometime in 2014. Later on, a life-threatening PE recurred in January 2015, so he resumed the anticoagulation therapy.
Fortunately, the bilateral sequential lung transplantation that was performed in July 2015 in time saved his life. He has been living well without dyspnea and the echocardiography showed the normalizations of the once increased pulmonary arterial pressure and the once enlarged right ventricle of his heart. In addition, to the best of my knowledge, he was the first PVOD patient receiving lung transplantation in China.
We recommend that PVOD patients combined with PE should be treated with anticoagulation therapy indefinitely to prevent the recurrence of life-threatening PE until they get a chance for lung transplantation.
肺静脉闭塞性疾病(PVOD)是一种罕见的肺动脉高压(PAH)形式。口服抗凝治疗仅限于特发性PAH(IPAH)患者,但PVOD患者未被推荐使用口服抗凝治疗,因为隐匿性肺出血在PVOD中是常见表现。
我们报告一例PVOD患者,该患者被误诊为IPAH达5年,伴有进行性加重的呼吸困难和两次肺栓塞(PE)发作。
通过对切除的肺标本进行活检,确诊为PVOD合并PE。
他于2010年7月开始口服抗凝药物华法林治疗首次发作的PE,病情保持稳定约4年,直到2014年某个时候他自行停用抗凝治疗。后来,2015年1月再次发生危及生命的PE,于是他重新开始抗凝治疗。
幸运的是,2015年7月及时进行的双侧序贯肺移植挽救了他的生命。他现在生活良好,没有呼吸困难,超声心动图显示曾经升高的肺动脉压和曾经扩大的右心室已恢复正常。此外,据我所知,他是中国首例接受肺移植的PVOD患者。
我们建议,PVOD合并PE的患者应无限期接受抗凝治疗,以预防危及生命的PE复发,直到他们有机会接受肺移植。